123 related articles for article (PubMed ID: 36039444)
1. Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells.
Asanuma K; Nakamura T; Nakamura K; Hagi T; Okamoto T; Kita K; Matsuyama Y; Yoshida K; Asanuma Y; Sudo A
Anticancer Res; 2022 Sep; 42(9):4319-4328. PubMed ID: 36039444
[TBL] [Abstract][Full Text] [Related]
2. STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.
Oi T; Asanuma K; Matsumine A; Matsubara T; Nakamura T; Iino T; Asanuma Y; Goto M; Okuno K; Kakimoto T; Yada Y; Sudo A
Int J Oncol; 2016 Dec; 49(6):2275-2284. PubMed ID: 27840900
[TBL] [Abstract][Full Text] [Related]
3. Screening for Synergistic Reagents With Pazopanib Against Osteosarcoma Using a Compound Library.
Yada Y; Asanuma K; Kakimto T; Okuno K; Okamoto T; Iino T; Nakamura T; Sudo A
Anticancer Res; 2024 Mar; 44(3):1071-1078. PubMed ID: 38423639
[TBL] [Abstract][Full Text] [Related]
4. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.
Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q
Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233
[TBL] [Abstract][Full Text] [Related]
6. Non‑covalent proteasome inhibitor PI‑1840 induces apoptosis and autophagy in osteosarcoma cells.
Chen Y; Chen H; Xie H; Yuan S; Gao C; Yu L; Bi Z
Oncol Rep; 2019 May; 41(5):2803-2817. PubMed ID: 30864717
[TBL] [Abstract][Full Text] [Related]
7. Combination of Everolimus and Bortezomib Inhibits the Growth and Metastasis of Bone and Soft Tissue Sarcomas via JNK/p38/ERK MAPK and AKT Pathways.
Nakamura K; Asanuma K; Okamoto T; Iino T; Hagi T; Nakamura T; Sudo A
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173935
[TBL] [Abstract][Full Text] [Related]
8. Combination of CDK4/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Anticancer Res; 2021 Jul; 41(7):3287-3292. PubMed ID: 34230123
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib sensitizes thyroid cancer to BRAF inhibitor
Tsumagari K; Abd Elmageed ZY; Sholl AB; Green EA; Sobti S; Khan AR; Kandil A; Murad F; Friedlander P; Boulares AH; Kandil E
Endocr Relat Cancer; 2018 Jan; 25(1):99-109. PubMed ID: 29269566
[TBL] [Abstract][Full Text] [Related]
10. Proteasome Inhibitor MG132 Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells and Inhibits Tumor Growth.
Sun F; Zhang Y; Xu L; Li S; Chen X; Zhang L; Wu Y; Li J
Oncol Res; 2018 May; 26(4):655-664. PubMed ID: 29191257
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors.
Yamashita AS; Baia GS; Ho JS; Velarde E; Wong J; Gallia GL; Belzberg AJ; Kimura ET; Riggins GJ
J Neurooncol; 2014 May; 118(1):83-92. PubMed ID: 24668609
[TBL] [Abstract][Full Text] [Related]
12. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
[TBL] [Abstract][Full Text] [Related]
14. Inositol polyphosphate-4-phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3-kinase/protein kinase B pathway.
Li D; Yang J; Ma H; Sun C; Feng R
J Cell Biochem; 2018 Dec; 119(12):9899-9909. PubMed ID: 30132953
[TBL] [Abstract][Full Text] [Related]
15. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
[TBL] [Abstract][Full Text] [Related]
17. 15,16-dihydrotanshinone I Induces Apoptosis and Inhibits the Proliferation, Migration of Human Osteosarcoma Cell Line 143B in vitro.
Chen X; Li Q; He Y; Du H; Zhan Z; Zhao H; Shi J; Ye Q; Hu J
Anticancer Agents Med Chem; 2017; 17(9):1234-1242. PubMed ID: 26478521
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231.
Xu T; Liu P; Li Q; Shi C; Wang X
Taiwan J Obstet Gynecol; 2020 Nov; 59(6):828-834. PubMed ID: 33218396
[TBL] [Abstract][Full Text] [Related]
19. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
20. Calycosin, a Phytoestrogen Isoflavone, Induces Apoptosis of Estrogen Receptor-Positive MG-63 Osteosarcoma Cells via the Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Sun H; Yin M; Qian W; Yin H
Med Sci Monit; 2018 Sep; 24():6178-6186. PubMed ID: 30182951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
